

**HER2-POSITIVE TARGETED THERAPY  
SALES AT EX-MANUFACTURER PRICE  
U.S. DOLLARS BY PRODUCT  
Q4 2012 – Q3 2014**

	2012	2013			
	Q4	Q1	Q2	Q3	Q4
<b>IV</b>					
Herceptin®	\$481,929,627	\$486,715,580	\$483,299,055	\$486,184,532	\$494,688,423
Kadcyla®		\$14,328,948	\$63,999,957	\$78,256,141	\$82,852,340
Perjeta®	\$34,208,377	\$43,543,924	\$49,544,835	\$52,681,394	\$88,655,837
<b>Non-IV</b>					
Tykerb®	\$31,138,049	\$29,985,339	\$26,126,981	\$24,222,882	\$22,848,420
Total	\$547,276,053	\$574,573,791	\$622,970,828	\$641,344,949	\$689,045,020
<b>IV</b>					
Herceptin®	88.1%	84.7%	77.6%	75.8%	71.8%
Kadcyla®		2.5%	10.3%	12.2%	12.0%
Perjeta®	6.3%	7.6%	8.0%	8.2%	12.9%
<b>Non-IV</b>					
Tykerb®	5.7%	5.2%	4.2%	3.8%	3.3%
Total	100.0%	100.0%	100.0%	100.0%	100.0%

Notes & Sources:

Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer with chemotherapy. See, e.g., Exhibit 2317. In contrast:

Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.

Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.

Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2224. (These assertions and sources can be found in the report.)

Includes brand values.

Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'

Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'

Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'

Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'

Values reflect field 'Sales \$'.

Percentage calculated as percent of quarterly total.

Products identified from Exhibit 2103 and Exhibit 2224.

Data from IMS Health.